达比加群酯临床应用的几点讨论

郑雪; 蒲冬玉

doi:10.13201/j.issn.1001-1439.2015.08.003

达比加群酯临床应用的几点讨论

郑雪^1, ,,
蒲冬玉²

- 1. 淄博市中心医院临床药理学教研室(山东淄博, 255036);
- 2. 淄博市中心医院心内科

详细信息

通讯作者: 郑雪,E-mail:15206699616@163.com

中图分类号: R973.2

收稿日期: 2014-12-10

Discussion about Dabigatran Etexilate in Clinical Application

ZHENG Xue^1, ,,
PU Dongyu²

- 1. Department of Clinical Pharmacology, Central Hospital of Zibo, Zibo, Shandong, 255036, China;
- 2. Department of Cardiology, Central Hospital of Zibo

More Information

Corresponding author: ZHENG Xue, E-mail: 15206699616@163.com

Received Date: 10 December 2014

摘要

摘要: 新型口服抗凝药物达比加群酯较华法林具有许多药代学优点，多项大型临床试验也得出疗效不劣于华法林的结论。本文对达比加群酯进行临床评价，对剂量选择和特殊人群用药、与出血有关的不良反应、解毒剂进展及出血的解决办法等进行分析和总结。
- 达比加群酯 /
- 临床评价 /
- 不良事件 /
- 出血处理
Abstract: Novel oral anticoagulant has many advantages in pharmacokinetics compared with warfarin, and a number of large-scale clinical trials have reached an agreement that the effect of dabigatran etexilate is not inferior to warfarin. The clinical use of dabigatran is discussed and summarized in this article, including dose selection, use in special populations, bleeding-related adverse events, antidote and and bleeding solution.
- dabigatran /
- clinical evaluation /
- adverse events /
- treatment of bleeding

HTML全文

参考文献(21)

[1]	HOUSTON D S, ZARYCHANSKI R. Dablgatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med, 2009, 361:2671, 2674-2675.
[2]	CONNOLLY S J, WALLENTIN L, EZEKOWITZ M D, et al.The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study[J]. Circulation, 2013, 128:237-243.
[3]	REILLY P A, LEHR T, HAERTTER S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients:the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)[J]. J Am Coll Cardiol, 2014, 63:321-328.
[4]	PARE G, ERIKSSON N, LEHR T, et al.Genetic determinants of dabigatran plasma levels and their relation to bleedin[J].Circulation, 2013, 127:1404-1412.
[5]	YATES S W. Novel oral anticoagulants for stroke prevention in atrial fibrillation:a focus on the older patient[J]. Int J Gen Med, 2013, 21:167-180.
[6]	BARCO S, CHEUNG Y W, EIKELBOOM J W, et al.New oral anticoagulants in elderly patients[J]. Best Pract Res Clin Haematol, 2013, 26:215-224.
[7]	KIM J, YADAVA M, AN I C, et al.Coagulopathy and extremely elevated PT/INR after dabigatran etexilate use in a patient with end-stage renal disease[J]. Case Rep Med, 2013, 2013:131395.
[8]	NAKAJIMA M, UCHIYAMA T, ADACHI A, et al.A case of advanced colon cancer with atrial fibrillation and the use of dabigatran for safe chemotherapy using fluoropyrimidine-based antitumor agents[J].Gan To Kagaku Ryoho, 2013, 40:1101-1103.
[9]	DONALDSON M, NORBECK A O.Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic[J]. Pharm Pract (Granada), 2013, 11:90-95.
[10]	CLEMENS A, FRAESSDORF M, FRIEDMAN J. Cardiovascular outcomes during treatment with dabigatran:comprehensive analysis of individual subject data by treatment[J]. Vasc Health Risk Manag, 2013, 9:599-615.
[11]	HORI M, CONNOLLY S J, ZHU J, et al.Dabigatran versus warfarin:effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation[J]. Stroke, 2013, 44:1891-1896.
[12]	CHATTERJEE S, SARDAR P, BIONDI-ZOCCAI G, et al. New oral anticoagulants and the risk of intracranial hemorrhage:traditional and bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation[J].JAMA Neurol, 2013, 70:1486-1490.
[13]	HERNANDEZ I, BAIK S H, PINERA A, et al. Risk of bleeding with dabigatran in atrial fibrillation[J]. JAMA Intern Med, 2015, 175:18-24.
[14]	GRAHAM D J, REICHMAN M E, WERNECKE M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation[J]. Circulation, 2015, 131:157-164.
[15]	PRAGST I, ZEITLER S H, DOERR B, et al.Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model[J]. J Thromb Haemost, 2012, 10:1841-1848.
[16]	EERENBERG E S, KAMPHUISEN P W, SIJPKENS M K, et al.Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate:a randomized, placebo-controlled, crossover study in healthy subjects[J].Circulation, 2011, 124:1573-1579.
[17]	MARLU R, HODAJ E, PARIS A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban:a randomised crossover ex vivo study in healthy volunteers[J]. Thromb Haemost, 2012, 108:217-224.
[18]	谭胜蓝, 周新民, 彭娟, 等.逆转达比加群酯抗凝活性的研究进展和处理建议[J].中国临床药理学与治疗学, 2012, 17(12):1413-1418.
[19]	中华心血管病杂志编辑委员会血栓栓塞防治循证工作组.达比加群酯用于非瓣膜病心房颤动患者卒中预防的临床应用建议[J].中华心血管病杂志, 2014, 42(3):188-192.
[20]	KUMAR R, SMITH R E, HENRY B L. A review of and recommendations for the management of patients with life-threatening dabigatran-associated hemorrhage:a single-center university hospital experience[J]. J Intensive Care Med, 2014,[Epub ahead of print]
[21]	KOMÓCSI A, VOROBCSUK A, KEHL D, et al.Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome:systematic review and meta-analysis of randomized controlled trials[J]. Arch Intern Med, 2012, 172:1537-1545.